Keyphrases
Adjusted Dose
66%
Angioedema Attack
50%
C1 Esterase Inhibitor
16%
C1 Inhibitor
33%
Clinical Outcomes
16%
Ecallantide
16%
Emergency Procedures
16%
Fixed-dose Combination
33%
Head-to-head Comparison
16%
Hereditary Angioedema
100%
Icatibant
16%
Indirect Comparison
16%
Laryngeal Attacks
100%
Life-threatening
33%
Median Time
16%
Medical Therapy
100%
Optimal Treatment
16%
Plasma-derived
50%
Rare Diseases
16%
Recombinant
16%
Single Body
16%
Symptom Onset
33%
Symptom Relief
50%
Time to Onset
33%
Treatment Efficacy
16%
Treatment Options
33%
Treatment Response
33%
Treatment Safety
16%
Upper Airway
16%
Medicine and Dentistry
Body Weight
83%
Clinical Study
16%
Combination Therapy
100%
Complement Component C1s Inhibitor
100%
Ecallantide
16%
Edema
16%
Hereditary Angioedema
100%
Icatibant
16%
Isoniazid
50%
Prospective Study
16%
Rare Disease
16%
Treatment Response
33%
Pharmacology, Toxicology and Pharmaceutical Science
Angioneurotic Edema
100%
Clinical Study
16%
Combination Therapy
100%
Complement Component C1s Inhibitor
100%
Ecallantide
16%
Edema
16%
Icatibant
16%
Isoniazid
50%
Prospective Study
16%
Rare Disease
16%
Biochemistry, Genetics and Molecular Biology
Body Weight
83%
C1-Inhibitor
100%
Clinical Study
16%
Ecallantide
16%
Hereditary Angioedema
100%
Prospective Study
16%